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ABSTRACT
Aims: To describe the experience of the Toxoplasmosis Laboratory of Infectious Disease Department University 
of Pavia, IRCCS Foundation, San Matteo Polyclinic Pavia, a reference laboratory for diagnosis of toxoplasmosis, 
in the investigation of women with suspected acute toxoplasmosis. Methods: All sera were tested with LIAISON® 
Toxo IgM and IgG II, Toxo IgG Avidity II kits (DiaSorin, Saluggia, Italy), VIDAS Toxo IgG II and Toxo IgG Avidity 
(bioMérieux, Marcy l’Etoile, France), IgM ISAGA (bioMérieux, Marcy l’Etoile, France) and ETI-TOXOK-A reverse 
PLUS (DiaSorin, Saluggia, Italy). When required (IgG negative/IgM positive women), IgG/IgM Western Blot II 
(LDBio, Lyon, France) was also performed. Prenatal diagnosis on amniotic fluid was done by nested PCR. All 
newborns were followed up to one year of age in order to exclude or confirm the diagnosis of congenital toxoplasmosis. 
All pregnant women with acute or undetermined stages of infection were treated. Results: In the course of 2007, 236 
women with suspected acute (IgM-positive) Toxoplasma infection were followed up. In the reference laboratory, 91 
women had test results indicating acute toxoplasmosis, and 10 had undetermined status of infection. These 101 patients 
represented 42.8% of the 236 women referred. Acute toxoplasmosis could be excluded in the remaining 135 patients, 
of whom 53 were non-immune. Three infected newborns were observed, all from mothers tested for the first time 
during the third trimester of pregnancy. Conclusions: The role of a reference laboratory in suspected toxoplasmosis 
acquired during pregnancy is crucial to date the infection and discriminate between seroconversion and false positive 
anti-Toxoplasma IgM antibodies. This avoids unnecessary anxiety in immune women, provides correct counseling 
about primary prevention and periodic testing for seronegative ones, and allows early treatment and follow-up of 
pregnant women with acute infection and their newborns.
Keywords: TOXOPLASMOSIS, CONGENITAL;  TOXOPLASMOSIS/diagnosis; Toxoplasma gondii; PRENATAL DIAGNOSIS; 
PRENATAL  CARE;  PREGNANCY  COMPLICATIONS,  INFECTIOUS;  CROSS-SECTIONAL  STUDIES;  REFERENCE 
CENTERS; FEMALE; PREGNANCY; SCREENING.
INTRODUCTION
Screening  for  toxoplasmosis  is  not  mandatory 
in Italy, but National Health Service reimbursement 
is provided for one test before pregnancy to assess 
immune status and a monthly follow-up for seronegative 
women, as well as after confirmed acute infection 
(DPR 245 10/09/98). Seroprevalence for Toxoplasma 
gondii antibodies has dramatically decreased in the 
last decades in Italy as well as in many other European 
Countries.1 In our region it was 48% in 1981,2 and now 
has dropped to 22% for Italian women and 33% for   
immigrants.3 
Though screening is not mandatory, risk awareness 
causes almost 85% of pregnant women to be tested for 
the first time during the first trimester of pregnancy. 
Conversely, only few women are tested for Toxoplasma 
antibodies before becoming pregnant, usually only 
in cases of in vitro fertilization. In addition, most 
seronegative women undergo serological tests about 
three  times  during  pregnancy,  with  a  significant 36  Sci Med. 2010;20(1):35-39
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difference  in  number  of  sampling  between  Italian 
and immigrant women.3 At the start of the screening 
program,  1.7%  of  women  were  positive  for  IgM, 
and  were  therefore  referred  as  outpatients  to  the 
Infectious Disease Clinic, IRCCS San Matteo Hospital 
Foundation, Pavia, Italy, for further investigation. Our 
experience as a reference laboratory from January to 
December 2007 is described here.
METHODS
The  study  included  all  pregnant  women  with 
suspected toxoplasmosis acquired during pregnancy 
referred to the Infectious Disease Clinic, IRCCS San 
Matteo Hospital Foundation, Pavia, Italy, for further 
investigation.
At the reference laboratory, all sera were tested 
with LIAISON® Toxo IgM and IgG II kits (DiaSorin, 
Saluggia, Italy), VIDAS Toxo IgG II (bioMérieux, 
Marcy  l’Etoile,  France),  and  with  the  following 
confirmatory tests: LIAISON® Toxo IgG Avidity II 
(DiaSorin,  Saluggia,  Italy);  VIDAS  Toxo  IgG  II 
Avidity (bioMérieux, Marcy l’Etoile, France); IgG/
IgM Western Blot II (LDBio, Lyon, France); IgM 
ISAGA (bioMérieux, Marcy l’Etoile, France); and 
ETI-TOXOK-A reverse PLUS (DiaSorin, Saluggia 
Italy). A  nested  polymerase  chain  reaction  (PCR) 
(Clonit,  Milan,  Italy)  was  performed  with  target 
gene AF146527 on amniotic fluid in patients with 
confirmed acute infections who underwent prenatal   
diagnosis.
True  seroconversion  was  defined  by  positive 
IgM antibodies confirmed with IgM ISAGA test and 
with type II Western Blot. Patients were managed 
according  to  our  protocol  illustrated  in  Figures  1   
and 2.
All newborns were followed up to one year of 
age in order to exclude or confirm the diagnosis of 
congenital toxoplasmosis.4 All pregnant women with 
acute and undetermined stages of infection in the 
second trimester were treated with pyrimethamine, 
sulfadiazine and folinic acid.
Figure 1. Prenatal serological screening for toxoplasmosis. Protocol of the Infectious Disease Clinic, IRCCS San Matteo 
Hospital Foundation, Pavia, Italy. 
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RESULTS
In the course of 2007, 236 women with suspected 
acute  (IgM  positive)  Toxoplasma  infection  were 
followed up in the reference laboratory. Thirty five 
(15%) were tested before pregnancy, 134 (57%) during 
the first trimester of pregnancy, 45 (19%) during the 
second trimester, and 22 (9%) during the third trimester.
In the reference laboratory, 91 women had test 
results indicating acute toxoplasmosis, and 10 had 
undetermined status of infection. These 101 patients 
represented 42.8% of the 236 women referred. Acute 
toxoplasmosis could be excluded in the remaining 
135  patients,  of  whom  53  were  non-immune 
(Table 1).
Table 1. Results of one year experience on 236 women with suspected acute toxoplasmosis (positive anti-Toxoplasma 
IgM), referred to the Infectious Disease Clinic, IRCCS San Matteo Hospital Foundation, Pavia, Italy (reference 
laboratory), for further investigation.
Results in the reference laboratory
First test with positive anti-Toxoplasma IgM
Total Before pregnancy 
35 (15%)
First trimester 
134 (57%)
Second trimester 
45 (19%)
Third trimester 
22 (9%) 
Non Immune * 14 19 11 9 53
Immune † 11 71 0 0 82
Acute Infection ‡  
(cases of confirmed seroconversion in pregnancy ‡) 
10
(0)
44
(10)
25
(12)
12
(11)
91 
(33)
Undetermined status of infection § 0 0 9 1 10
Congenital infection 0 0 0 3 3
* Non immune: IgG/IgM negative.
†  Immune: IgG positive/IgM negative or IgG/IgM positive and high IgG avidity index.
‡  Acute infection and confirmed seroconversion in pregnancy as defined in Methods.
§ Undetermined status of infection: patients came too late to the reference laboratory.
Figure 2. Diagnostic flow-chart for Toxoplasma gondii acute infection in pregnancy. Protocol of the Infectious 
Disease Clinic, IRCCS San Matteo Hospital Foundation, Pavia, Italy.
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Of the 35 women tested before pregnancy, 14 
resulted non-immune, 11 immune, and 10 with acute 
infection (Table 1).
Of  134  sera  collected  from  women  in  the  first 
trimester  of  pregnancy,  19  resulted  non-immune, 
71 with past infection, and 44 with acute infection 
(Table 1). Twenty nine sera were negative for IgG and 
positive for IgM, but of these, only 10 patients had true 
seroconversion (positive IgM antibodies confirmed with 
IgM ISAGA test and/or with type II Western Blot, as 
defined in Methods). In these 10 cases IgG appeared, 
even if its production was delayed and lowered by 
therapy, as described elsewhere.5 In 105 sera positive 
for IgG and IgM, acute infection was ruled out on the 
basis of high IgG avidity index in 71 women. All women 
with acute infection were treated with spiramycin and 31 
underwent prenatal diagnosis with negative results. No 
infected newborns were observed in this group.
Forty-five women were tested for the first time 
in the second trimester of pregnancy, of whom 11 
resulted non-immune, 25 with acute infection, and 
9 with undetermined status (Table 1). Twenty-three 
scored negative for IgG and positive for IgM, of whom 
12 had confirmed seroconversion (as defined above), 
and in 11 patients the infection was excluded because 
of a negative IgM ISAGA test and a negative type 
II IgG/IgM Western Blot. In all these 11 cases, after 
therapy discontinuation, no specific IgG appeared. In 
13 women, sera scored positive for IgG and IgM with 
low IgG avidity index. Although a low avidity index 
is not always related to an acute infection (sometimes 
the avidity index remains persistently low), we could 
not exclude acute infection during pregnancy, so we 
treated and followed up these patients like we did with 
acute infections.6 Hence, the possibility of infection 
occurred during pregnancy was considered in 25 cases, 
and infection status was undetermined in nine cases that 
came to our laboratory too late during pregnancy. Nine 
women underwent prenatal diagnosis and all scored 
negative. No infected newborns were observed.
Twenty-two women with suspected acute infection 
were tested for the first time during the third trimester 
of  pregnancy.  In  the  reference  laboratory,  acute 
infection was considered in 12 patients, of whom 11 
patients were defined as having seroconversion during 
pregnancy and one woman with low avidity index 
was treated and followed up as an acute case. In this 
group we observed one case of undetermined stage of 
infection (IgG and IgM positive, high IgG index) and 
10 negative women. All acute and undetermined stages 
of infection were treated with pyrimethamine and 
sulfadiazine. Three infected newborns were observed 
In this group. (Table 1)
The only newborn that showed severe signs of 
disease was born from an immigrant mother never 
tested before the 28th week of pregnancy. This woman 
was  addressed  to  our  laboratory  when  ultrasound 
abnormalities (hydrocephalus, cerebral calcifications) 
suggested Toxoplasma infection. High IgG titres and 
IgM and IgA positive results confirmed the diagnosis 
of maternal toxoplasmosis, even if IgG avidity index 
was already high. We could not define the gestational 
age at which seroconversion occurred and classified 
this infection as undetermined. The woman had not 
received therapy until diagnosis was established in our 
laboratory. 
DISCUSSION
Seroprevalence data in pregnant women of our 
region showed a decrease during the last 30 years like in 
many other European Countries.1 This fact may be due 
to a change in dietary habits, although seroprevalence 
in transplant recipients is higher (about 50%, Meroni 
V, unpublished data). Nevertheless, infection may still 
occur.
All women should be tested before pregnancy 
to  evaluate  their  immunological  status  regarding 
toxoplasmosis,  and  should  receive  counselling  on 
toxoplasmosis  in  pregnancy.  Screening  system 
in Italy is efficient in recruiting women in the first 
trimester of pregnancy, but we need to increase the 
use of preconceptional screening. Women should be 
encouraged to perform tests for toxoplasmosis before 
and during early pregnancy. This screening must be 
consistently based on specific IgG and IgM detection, 
and cases suspected of acute toxoplasmosis should 
be referred to a reference laboratory. This allows to 
reassure immune women and to avoid unnecessary 
treatment and follow up of pregnant women and their 
newborns.
All women were referred to our laboratory for 
the presence of anti-Toxoplasma IgM antibodies. The 
presence of anti-Toxoplasma IgM, however, is not 
synonymous with acute infection. The use of different 
tests, that only a reference laboratory can perform, 
allowed us to exclude acute infection in many cases. 
These tests have different specificity and sensitivity   
and were useful to date the infection. For instance, 
Liaison Toxo IgG is more sensitive and could detect 
serocoversion earlier than VIDAS Toxo IgG II. IgM 
ISAGA is more specific than Liaison IgM but could 
detect anti-Toxoplasma IgM too long. IgG/IgM Western 
Blot II is very specific because employs only purified 
antigens recognized by the specific antibodies at the 
beginning of infection.  Sci Med. 2010;20(1):35-39  39
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No infected newborn was observed when infection 
occurred during the first and second trimesters, or from 
mothers whose infection in pregnancy was excluded. 
Unfortunately, for 11 women it was impossible to 
define the time of infection, because they arrived to 
the reference laboratory in the last weeks of pregnancy. 
They were not correctly treated, and among them we 
recorded the only case of severe congenital toxo- 
plasmosis. 
All patients who were referred in an appropriate 
time received the proper therapy, and in many cases 
prenatal diagnosis was performed. All PCR negative 
pregnant women gave birth to uninfected newborns.
Within  this  scenario,  in  which  acute  infection 
was confirmed or indeterminate in only 42.8% of 
cases, the role of a reference laboratory in suspected 
toxoplasmosis acquired during pregnancy is really 
crucial to date the infection and discriminate between 
seroconversion and false positive anti-Toxoplasma IgM 
antibodies. This avoids unnecessary anxiety in immune 
women, provides correct counseling about primary 
prevention and periodic testing for seronegative ones, 
and allows early treatment and follow up of pregnant 
women with acute infection and their newborns.
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